Aposcience AG received the Recommendations of the Data Safety Monitoring Board (DSMB). On 30 July 2021, three experts in the field of wound healing, after revising the data of the Lead In-Phase of the MARSYAS II trial (EudraCT…
On 27 May 2021 Aposcience AG received the notification of the Paul-Ehrlich-Institut of the approval of the clinical phase II trial in diabetic foot ulcer (DFU), MARSYAS II, for Germany. Currently, the MARSYAS II trial has…
Aposcience AG was granted approval by the Austrian health agency BASG to start a clinical phase II study in the indication diabetic foot ulcers of its novel product APOSEC, the secretome of stressed Peripheral Blood Mononuclear…
On Sept. 6, 2019, the United States Patent and Trademark Office issued a Notice of Allowance concerning the US patent application No. 13/140,120 “Pharmaceutical preparation”, the patent of APOSEC for the treatment of internal…
Maryas I – clinical phase 1 study was completed on 5 February 2016
Beer L et al. Analysis of the Secretome of Apoptotic Peripheral Blood Mononuclear Cells: Impact of Released Proteins and Exosomes for Tissue Regeneration – was recently published in Scientific Reports. Sci Rep. 2015 Nov…
The European Patent Office informed us its intention to grant our patent application for the treatment of systemic conditions with APOSEC.
New Paper accepted in Experimental Neurology
On 23 Oct. 2014 the clinical phase I trial Marsyas I, a prospective, single-Center, randomised, double-blinded, placebo controlled, dose finding phase I study in the indication skin wound healing was initiated.
On 25 April 2014 the Austrian Health Authority AGES issued the approval for the production of allogeneic and autologous APOSEC for clinical testing in the APOSEC GMP production facilty at the Blood Bank Linz.
End of content
End of content